Diabetes | Arterial disease | Retinal disease | |||||||
---|---|---|---|---|---|---|---|---|---|
Predicts | Effect of lifestyle interventions | Effect of drugs | Predicts | Effect of lifestyle interventions | Effect of drugs | Predicts | |||
Impaired glucose tolerance (7.8-11.1 mmol/L)* | +++ | +++ (delays) | +++ (disguises) | ? | + | ||||
+ (prevents) | + (prevents) | ||||||||
Impaired fasting glucose (6.1-6.9 mmol/L) | ++ | ? | (+)† | + | ? | ? | ? | ||
Expanded impaired fasting glucose (5.6-6.9 mmol/L) | + | ? | ? | + | ? | ? | ? | ||
Borderline HbA1c (6.0-6.4%) | ++ | ? | ? | + | ? | ? | ? | ||
Expanded borderline HbA1c (5.7-6.4%) | + | ? | ? | + | ? | ? | ? |
*Two hours after 75 g glucose load.
† The DREAM Study included 14% of subjects with impaired fasting glucose in whom rosiglitazone showed comparable effects to those with impaired glucose tolerance at the end of the intervention,37 although this group was not reported separately after drug washout.45